Anti-copper therapies in Alzheimer's disease: New concepts

Recent Patents on CNS Drug Discovery

Volumn 4, Issue 3, 2009, Pages 209-219

  Squitti, Rosanna ^a,b   Zito, Giancarlo ^a  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

'Free' copper; Alzheimer's disease; Anti copper agents; Ceruloplasmin; Metal chelators; Metal complexing agents; Serum copper; Zinc therapy

Indexed keywords

1,2 BIS(2 AMINOPHENYLOXY)ETHANE N,N,N',N' BIS(2 OCTADECYLOXYETHYL)ESTER N,N' DISODIUM; ALUMINUM; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTI COPPER COMPLEXING AGENT; BATHOCUPROINE; BATHOPHENANTHROLINE; BETA SECRETASE; CERULOPLASMIN; CHELATING AGENT; CLIOQUINOL; COPPER; CUPRIC ION; DEFEROXAMINE; DP 109; N,N,N',N' TETRAKIS(2 PYRIDYLMETHYL)ETHYLENEDIAMINE; OROTATE COPPER; PBT2; PENICILLAMINE; PENTETIC ACID; PHENANTHROLINE; PLACEBO; TETRATHIOMOLYBDATE AMMONIUM; UNCLASSIFIED DRUG; WILZIN; ZINC ACETATE; ZINC ASPARTATE; ZINC DERIVATIVE; ZINC SULFATE;

ALZHEIMER DISEASE; ANEMIA; CERULOPLASMIN BLOOD LEVEL; CHEMICAL INTERACTION; CLINICAL TRIAL; COPPER BLOOD LEVEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG TOLERABILITY; HEART ARREST; HUMAN; IN VITRO STUDY; LEUKOPENIA; LIVER TOXICITY; METAL BINDING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; SUBACUTE MYELOOPTIC NEUROPATHY; TRACE METAL BLOOD LEVEL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VASCULAR AMYLOIDOSIS; WILSON DISEASE;

ALZHEIMER DISEASE; ANIMALS; CHELATING AGENTS; CLINICAL TRIALS AS TOPIC; COPPER; HUMANS; PATENTS AS TOPIC;

EID: 70449514549     PISSN: 15748898     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488909789104802     Document Type: Review

References (105)

1. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 2008; 192(1): 106-113.
2. Hardy JA, Higgins GA. Alzheimer's disease: The amyloid cascade hypothesis. Science 1992; 256(5054): 184-185.
3. Crouch PJ, White AR, Bush AI. The modulation of metal bioavailability as a therapeutic strategy for the treatment of Alzheimer's disease. FEBS J 2007; 274(15): 3775-3783. (Pubitemid 47087674)
4. Lovell MA, Robertson JD, Teesdale WJ, et al. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998; 158(1): 47-52.
5. Farfara D, Lifshitz V, Frenkel D. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. J Cell Mol Med 2008; 12(3): 762-780.
6. Edison P, Archer HA, Gerhard A, et al. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 2008; 32(3): 412-419.
7. Bush AI, Tanzi RE. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 2008; 5(3): 421-432. (Pubitemid 351952485)
8. Opazo C, Huang X, Cherny RA, et al. Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem 2002; 277(43): 40302-40308. (Pubitemid 35215603)
9. Angeletti B, Waldron KJ, Freeman KB, et al. BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper. J Biol Chem 2005; 280(18): 17930-17937. (Pubitemid 41389034)
10. Lin R, Chen X, Li W, et al. Exposure to metal ions regulates mRNA levels of APP and BACE1 in PC12 cells: blockage by curcumin. Neurosci Lett 2008; 440(3): 344-347.
11. Barnham KJ, McKinstry WJ, Multhaup G, et al. Structure of the Alzheimer's disease amyloid precursor protein copper binding domain. A regulator of neuronal copper homeostasis. J Biol Chem 2003; 278(19): 17401-17407. (Pubitemid 36799626)
12. Hesse L, Beher D, Masters CL, et al. The beta A4 amyloid precursor protein binding to copper. FEBS Lett 1994; 349(1):109-116. (Pubitemid 2119590)
13. White AR, Multhaup G, Galatis D, et al. Contrasting, species-dependent modulation of copper-mediated neurotoxicity by the Alzheimer's disease amyloid precursor protein. J Neurosci 2002; 22(2): 365-376. (Pubitemid 34049074)
14. Smith DG, Cappai R, Barnham KJ. The redox chemistry of the Alzheimer's disease amyloid beta peptide. Biochim Biophys Acta 2007; 1768(8): 1976-1990. (Pubitemid 47125850)
15. Multhaup G, Schlicksupp A, Hesse L, et al. The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I). Science 1996; 271(5254): 1406-1409. (Pubitemid 26089474)
16. Multhaup G, Ruppert T, Schlicksupp A, et al. Reactive oxygen species and Alzheimer's disease. Biochem Pharmacol 1997; 54(5): 533-539. (Pubitemid 27405186)
17. Huang X, Cuajungco MP, Atwood CS, et al. Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 1999; 274(52): 37111-37116. (Pubitemid 30016785)
18. Crouch PJ, Blake R, Duce JA, et al. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci 2005; 25(3): 672-679.
19. Bellingham SA, Lahiri DK, Maloney B, La Fontaine S, Multhaup G, Camakaris J. Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene. J Biol Chem 2004; 279(19): 20378-20386. (Pubitemid 38623484)
20. Bush AI, Pettingell WH, Multhaup G, et al. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 1994; 265(5177): 1464-1467. (Pubitemid 24306803)
21. Barnham KJ, Ciccotosto GD, Tickler AK, et al. Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem 2003; 278(44): 42959-42965.
22. Atwood CS, Scarpa RC, Huang X, et al. Characterization of copper interactions with alzheimer amyloid beta peptides: Identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem 2000; 75(3): 1219-1233. (Pubitemid 30660512)
23. Huang X, Atwood CS, Hartshorn MA, et al. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999; 38(24): 7609-7616. (Pubitemid 29289332)
24. White AR, Multhaup G, Maher F, et al. The Alzheimer's disease amyloid precursor protein modulates copper-induced toxicity and oxidative stress in primary neuronal cultures. J Neurosci 1999; 19(21): 9170-9179. (Pubitemid 30228069)
25. Cherny RA, Legg JT, McLean CA, et al. Aqueous dissolution of Alzheimer's disease abeta amyloid deposits by biometal depletion. J Biol Chem 1999; 274(33): 23223-23228. (Pubitemid 129529155)
26. Donnelly PS, Caragounis A, Du T, et al. Selective intracellular release of copper and zinc ions from bis(thiosemicarbazonato) complexes reduces levels of Alzheimer disease amyloid-beta peptide. J Biol Chem 2008; 283(8): 4568-4577.
27. Puglielli L, Friedlich AL, Setchell KD, et al. Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. J Clin Invest 2005; 115(9): 2556-2563. (Pubitemid 41266218)
28. Nelson TJ, Alkon DL. Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J Biol Chem 2005; 280(8): 7377-7387.
29. Sparks DL, Schreurs BG. Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci USA 2003; 100(19): 11065-11069.
30. Smorgon C, Mari E, Atti AR, et al. Trace elements and cognitive impairment: An elderly cohort study. Arch Gerontol Geriatr Suppl 2004; (9): 393-402. (Pubitemid 38822890)
31. Squitti R, Salustri C. Agents complexing copper as a therapeutic strategy for the treatment of Alzheimer's disease. Curr Alzheimer Res 2009 (in press).
32. Squitti R, Pasqualetti P, Dal Forno G, et al. Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 2005; 64(6): 1040-1046. (Pubitemid 40388458)
33. Squitti R, Barbati G, Rossi L, et al. Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF [beta]-amyloid, and h-tau. Neurology 2006; 67(1): 76-82. (Pubitemid 44305465)
34. Ohsawa I, Takamura C, Kohsaka S. The amino-terminal region of amyloid precursor protein is responsible for neurite outgrowth in rat neocortical explant culture. Biochem Biophys Res Commun 1997; 236(1): 59-65. (Pubitemid 27341839)
35. Rossjohn J, Cappai R, Feil SC, et al. Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. Nat Struct Biol 1999; 6(4): 327-331. (Pubitemid 129751275)
36. Bellingham SA, Ciccotosto GD, Needham BE, et al. Gene knockout of amyloid precursor protein and amyloid precursor-like protein-2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts. J Neurochem 2004; 91(2): 423-428.
37. Armendariz AD, Gonzalez M, Loguinov AV, Vulpe CD. Gene expression profiling in chronic copper overload reveals upregulation of Prnp and App. Physiol Genomics 2004; 20(1): 45-54. (Pubitemid 40388504)
38. Morris MC, Evans DA, Tangney CC, et al. Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neurol 2006; 63(8): 1085-1088.
39. Lam PK, Kritz-Silverstein D, Barrett Connor E, et al. Plasma trace elements and cognitive function in older men and women: the Rancho Bernardo study. J Nutr Health Aging 2008; 12(1): 22-27. (Pubitemid 351156011)
40. Maynard CJ, Cappai R, Volitakis I, et al. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem 2002; 277(47): 44670-44676. (Pubitemid 36159056)
41. Maynard CJ, Bush AI, Masters CL, Cappai R, Li QX. Metals and amyloid-beta in Alzheimer's disease. Int J Exp Pathol 2005; 86(3): 147-159.
42. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: A central role for bound transition metals. J Neurochem 2000; 74(1): 270-279.
43. Squitti R, Rossini PM, Cassetta E, et al. d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. Eur J Clin Invest 2002; 32(1): 51-59. (Pubitemid 36228383)
44. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch Neurol 2003; 60(12): 1685-1691. (Pubitemid 37521621)
45. Lannfelt L, Blennow K, Zetterberg H, et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: A phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008; 7(9): 779-786.
46. Kessler H, Bayer TA, Bach D, et al. Intake of copper has no effect on cognition in patients with mild Alzheimer's disease: A pilot phase 2 clinical trial. J Neural Transm 2008; 115(8): 1181-1187.
47. McLachlan CDR, Dalton AJ, Kruck TP, et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991; 337(8753): 1304-1308.
48. Constantinidis J. Treatment of Alzheimer's disease by zinc compounds. Drug Dev Res 1992; 27(1): 1-14.
49. Price KA, Crouch PJ, White AR. Therapeutic treatment of Alzheimer's disease using metal complexing agents. Recent Pat CNS Drug Discov 2007; 2(3): 180-187. (Pubitemid 350200290)
50. Huang X, Atwood CS, Moir RD, et al. Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors. J Biol Chem 1997; 272(42): 26464-26470. (Pubitemid 27458865)
51. Atwood CS, Perry G, Zeng H, et al. Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry 2004; 43(2): 560-568. (Pubitemid 38082580)
52. Lee JY, Friedman JE, Angel I, Kozak A, Koh JY. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging 2004; 25(10): 1315-1321. (Pubitemid 39299169)
53. Dedeoglu A, Cormier K, Payton S, et al. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. Exp Gerontol 2004; 39(11-12): 1641-1649. (Pubitemid 39585199)
54. Reznichenko L, Amit T, Zheng H, et al. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3- gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J Neurochem 2006; 97(2): 527-536.
55. Barnham KJ, Haeffner F, Ciccotosto GD, et al. Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J 2004; 18(12): 1427-1429. (Pubitemid 39561603)
56. Tickler AK, Smith DG, Ciccotosto GD, et al. Methylation of the imidazole side chains of the Alzheimer disease amyloid-beta peptide results in abolition of superoxide dismutase-like structures and inhibition of neurotoxicity. J Biol Chem 2005; 280(14): 13355-13363.
57. Bush, A.L., Huang, X., Atwood, C.S., Tanzi, R.E.: WO99045907 (1999).
58. Regland B, Lehmann W, Abedini I, et al. Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord 2001; 12(6): 408-414.
59. Ibach B, Haen E, Marienhagen J, Hajak G. Clioquinol treatment in familiar early onset of Alzheimer's disease: A case report. Pharmacopsychiatry 2005; 38(4): 178-179. (Pubitemid 41065045)
60. White AR, Du T, Laughton KM, et al. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent upregulation of metalloprotease activity. J Biol Chem 2006; 281(26): 17670-17680. (Pubitemid 44035565)
61. Barnham, K.J., Gautier, E., Kok, G., Krippner, G.: WO2004007461 (2004).
62. Kok, G.B., Leung, B.K.Y., Gautier, E.C.L., Barnham, K.J.: WO2004031161 (2004).
63. Adlard PA, Cherny RA, Finkelstein DI, et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008; 59(1): 43-55.
64. Bomboi G, Marchione F, Sepe-Monti M, De et al. Correlation between metal ions and clinical findings in subjects affected by Alzheimer's disease. Ann Ist Super Sanita 2005; 41(2): 205-212. (Pubitemid 43169865)
65. Gonzalez C, Martin T, Cacho J, et al. Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur J Clin Invest 1999; 29(7): 637-642. (Pubitemid 29322377)
66. Squitti R, Lupoi D, Pasqualetti P, et al. Elevation of serum copper levels in Alzheimer's disease. Neurology 2002; 59(8): 1153-1161. (Pubitemid 35192384)
67. Snaedal J, Kristinsson J, Gunnarsdottir S, Olafsdottir, Baldvinsson M, Johannesson T. Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease . A case-control study. Dement Geriatr Cogn Disord 1998; 9(5): 239-242. (Pubitemid 28377223)
68. Ozcankaya R, Delibas N. Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: Cross-sectional study. Croat Med J 2002; 43(1): 28-32. (Pubitemid 34157862)
69. Sedighi B, Shafa MA, Shariati M. A study of serum copper and ceruloplasmin in Alzheimer's disease in Kerman, Iran. Neurology Asia 2006; 11: 107-109.
70. Pajonk FG, Kessler H, Supprian T, et al. Cognitive decline correlates with low plasma concentrations of copper in patients with mild to moderate Alzheimer's disease. J Alzheimers Dis 2005; 8(1): 23-27. (Pubitemid 41267320)
71. Kessler H, Pajonk FG, Meisser P, et al. Cerebrospinal fluid diagnostic markers correlate with lower plasma copper and ceruloplasmin in patients with Alzheimer's disease. J Neural Transm 2006; 113(11): 1763-1769. (Pubitemid 44657672)
72. Walshe JM. Wilson's disease: The importance of measuring serum caeruloplasmin non-immunologically. Ann Clin Biochem 2003; 40(Pt 2): 115-121.
73. Chutkow JG. Evidence for uptake of nonceruloplasminic copper in the brain: Effect of ionic copper and amino acids. Proc Soc Exp Biol Med 1978; 158(1): 113-116.
74. Squitti R, Ventriglia M, Barbati G, Cassetta, et al. 'Free' copper in serum of Alzheimer's disease patients correlates with markers of liver function. J Neural Transm 2007; 114(12): 1589-1594. (Pubitemid 350212005)
75. Babiloni C, Squitti R, Del Percio C, et al. Free copper and resting temporal EEG rhythms correlate across healthy, mild cognitive impairment, and Alzheimer's disease subjects. Clin Neurophysiol 2007; 118(6): 1244-1260. (Pubitemid 46736024)
76. Zappasodi F, Salustri C, Babiloni C, et al. An observational study on the influence of the APOE-epsilon4 allele on the correlation between 'free' copper toxicosis and EEG activity in Alzheimer disease. Brain Res 2008; 1215: 183-189.
77. Squitti R, Pasqualetti P, Cassetta E, et al. Elevation of serum copper levels discriminates Alzheimer's disease from vascular dementia. Neurology 2003; 60(12): 2013-2014. (Pubitemid 36736031)
78. Raygani AV, Rahimi Z, Kharazi H, Tavilani H, Pourmotabbed T. Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer's disease. Neurosci Lett 2006; 408(1): 68-72. (Pubitemid 44466204)
79. Raygani AV, Zahrai M, Doosti M, Javadi E, Rezaei M, Pourmotabbed T. Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran. Neurosci Lett 2005; 375(1): 1-6. (Pubitemid 40139057)
80. Raygani AV, Zahrai M, Soltanzadeh A, Doosti M, Javadi E, Pourmotabbed T. Analysis of association between butyrylcholinesterase K variant and apolipoprotein E genotypes in Alzheimer's disease. Neurosci Lett 2004; 371(2-3): 142-146. (Pubitemid 39445362)
81. Kharrazi H, Vaisi-Raygani A, Rahimi Z, Tavilani H, Aminian M, Pourmotabbed T. Association between enzymatic and nonenzymatic antioxidant defense mechanism with apolipoprotein E genotypes in Alzheimer disease. Clin Biochem 2008; 41(12): 932-936.
82. Squitti R, Bressi F, Pasqualetti P, et al. Longitudinal prognostic value of serum "free" copper in patients with Alzheimer disease. Neurology 2009; 72(1): 50-55.
83. Opazo C, Luza S, Villemagne VL, et al. Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease. Aging Cell 2006; 5(1): 69-79. (Pubitemid 43348964)
84. Capo CR, Arciello M, Squitti R, et al. Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients. Biometals 2008; 21(3): 367-372.
85. Strozyk D, Launer LJ, Adlard PA, et al. Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid. Neurobiol Aging 2009: 30(7): 1068-1077.
86. Squitti R, Quattrocchi CC, Salustri C, Rossini PM. Ceruloplasmin fragmentation is implicated in 'free' copper deregulation of Alzheimer's disease. Prion 2008; 2(1): 23-27.
87. Schiefermeier M, Kollegger H, Madl C, et al. The impact of apolipoprotein E genotypes on age at onset of symptoms and phenotypic expression in Wilson's disease. Brain 2000; 123 Pt 3: 585-590. (Pubitemid 30099542)
88. Kessler H, Pajonk FG, Bach D, et al. Effect of copper intake on CSF parameters in patients with mild Alzheimer's disease: A pilot phase 2 clinical trial. J Neural Transm 2008; 115(12): 1651-1659.
89. Bayer TA, Schafer S, Simons A, et al. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci USA 2003; 100(24): 14187-14192. (Pubitemid 37499212)
90. Phinney AL, Drisaldi B, Schmidt SD, et al. in vivo Reduction of amyloid-beta by a mutant copper transporter. Proc Natl Acad Sci USA 2003; 100(24): 14193-14198.
91. Kanzer, S.H.: WO2008112824 (2008).
92. Marcellini M, Di Ciommo V, Callea F, et al. Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: A single-hospital, 10-year follow-up study. J Lab Clin Med 2005; 145(3): 139-143. (Pubitemid 40432363)
93. Hoogenraad TU, Van den Hamer CJ, Koevoet R, Korver EG. Oral zinc in Wilson's disease. Lancet 1978; 2(8102): 1262.
94. Hoogenraad TU, Koevoet R, de Ruyter Korver EG. Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration). Eur Neurol 1979; 18(3): 205-211. (Pubitemid 9237779)
95. Hoogenraad TU, Van Hattum J, Van den Hamer CJ. Management of Wilson's disease with zinc sulphate. Experience in a series of 27 patients. J Neurol Sci 1987; 77(2-3): 137-146. (Pubitemid 17231288)
96. Bush, A.I.S., Huang, X., Atwood, C.S., Tanzi, R.E.: US20067045531 (2006).
97. Gierhart, D.L., Dorey, K.C., Kelly, P.D.: WO2005117982 (2005).
98. Kong, X., Migneault, D., Valade, I., Wu, X., Gervais, F.: US20087414076 (2008).
99. Zhu, Z.: WO02034920A2 (2002).
100. Bush A.I., Huang, X., Atwood, C.S., Tanzi, R.E.: US20016323218 (2001).
101. Brewer, G.J.: US20087416741 (2008).
102. Yuzbasiyan-Gurkan V, Grider A, Nostrant T, Cousins RJ, Brewer GJ. Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction. J Lab Clin Med 1992; 120(3): 380-386.
103. Brewer GJ, Yuzbasiyan-Gurkan V, Dick RD. Zinc therapy of Wilson's disease: VIII. Dose-response studies. Trace Elem Exp Med 1990; 3: 227-234.
104. Brewer GJ, Yuzbasiyan-Gurkan V, Johnson V, Dick RD, Wang Y. Treatment of Wilson's disease with zinc XII: Dose regimen requirements. Am J Med Sci 1993; 305(4): 199-202. (Pubitemid 23124747)
105. Brewer GJ. The use of copper-lowering therapy with tetrathiomolybdate in medicine. Expert Opin Investig Drugs 2009; 18(1): 89-97.